TSPYL2 and neoplasm: Our analysis showed that patients of the TSPX-high group were diagnosed at earlier pathologic/tumor stages, as compared to those of the TSPX-low group, i.e., while 66% of patients of the TSPX-high group were at stage-I, only 45% patients of the TSPX-low group were at stage-I (p-value = 0.0027) (Figure 1C).